MM D37K

Drug Profile

MM D37K

Alternative Names: MM-D37K chimeric peptide; MMD37K

Latest Information Update: 30 Dec 2015

Price : $50

At a glance

  • Originator MetaMax
  • Class Cytostatics; Peptides
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Gastrointestinal cancer; Glioblastoma; Malignant melanoma

Most Recent Events

  • 31 May 2013 Pharmacodynamics & pharmacokinetics data from preclinical studies in Solid tumours presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
  • 23 Nov 2012 Preclinical trials in Solid tumours in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top